Faiz Mumtaz

Prof. Faiz Mumtaz


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Urology
Verified
Journal Article
Closed access
ARAvi Raman
Avi Raman
TKTeele Kuusk
Teele Kuusk
EHEoin R. Hyde
Eoin R. Hyde
LBLorenz U. Berger
Lorenz U. Berger
ABAxel Bex
Axel Bex
FMFaiz Mumtaz
Faiz Mumtaz

26 July 2017 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
MCMelanie Chan
Melanie Chan
ABAngela Barnicoat
Angela Barnicoat
FMFaiz Mumtaz
Faiz Mumtaz
MAMichael Aitchison
Michael Aitchison
LSLucy Side
Lucy Side
DGDaniel P. Gale
Daniel P. Gale
Fumarate hydratase (FH) deficiency is a rare autosomal recessive disorder which results in a major defect in cellular metabolism. It presents in infancy with progressive encephalopathy, hypotonia, seizures and failure to thrive and is often fatal in childhood. It is caused by mutations in the FH gene (1q42.1) that result in deficiency of the citric acid cycle enzyme fumarate hydratase, resulting in accumulation of fumaric acid. Heterozygous germline mutations in the FH gene predispose to an aggressive autosomal dominant inherited early-onset kidney cancer syndrome: hereditary leiomyomatosis and renal cell cancer (HLRCC). Cascade FH mutation screening enabled the early diagnosis of a renal tumour in an asymptomatic parent of a child with fumarate hydratase deficiency, resulting in timely and possibly life-saving treatment. While the theoretical risk of kidney cancer in parents of children with recessive fumarate hydratase deficiency is well recognized, to our knowledge this is the first report of a kidney tumour being detected in a parent by screening performed for this indication. This underscores the importance of offering lifelong kidney surveillance to such parents and other heterozygous relatives of children born with fumarate hydratase deficiency.

1 November 2000 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MKM. A. Khan
M. A. Khan
RCR. C. Calvert
R. C. Calvert
MSM. E. Sullivan
M. E. Sullivan
CTC. S. Thomson
C. S. Thomson
FMFaiz Mumtaz
Faiz Mumtaz
DMD. P. Mikhailidis
D. P. Mikhailidis
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.

27 July 2021 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
SFSergio Fernandez-Pello
Sergio Fernandez-Pello
NVNeeta Verma
Neeta Verma
TKTeele Kuusk
Teele Kuusk
ABAleksandra Berezowska
Aleksandra Berezowska
FMFaiz Mumtaz
Faiz Mumtaz
ABAxel Bex
Axel Bex

1 May 2013 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
HEHani Ertemi
Hani Ertemi
DLDavid H.W. Lau
David H.W. Lau
DMDimitri P. Mikhailidis
Dimitri P. Mikhailidis
FMFaiz Mumtaz
Faiz Mumtaz
CTCecil S. Thompson
Cecil S. Thompson

6 March 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
WSWendy Smith
Wendy Smith
JSJoseph Santiapillai
Joseph Santiapillai
Marilena LoizidouMarilena Loizidou
Marilena Loizidou
SMStuart Mazzone
Stuart Mazzone
MTMaxine G B Tran
Maxine G B Tran
FMFaiz Mumtaz
Faiz Mumtaz
Objectives: Cough occurring in patients with renal cell carcinoma (RCC) was first described in 1935 and is a frequently discussed symptom on patient forums. We aimed to systematically review the available evidence to explore the prevalence and risk factors for persistent cough in patients diagnosed with RCC to establish whether cough could be a presenting symptom of RCC. Design: This epidemiological systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 2020. Data sources: Medline, Embase, Science Citation Index, The Cochrane Library, ClinicalTrials.gov and the WHO trials register were searched without language restrictions until 1 June 2023. Eligibility criteria for selecting studies: We included articles of all study designs reporting cough in patients (18 years or older) with RCC attributed to the disease itself or to treatment. Data extraction and synthesis: Data from included articles was extracted using a preprepared and piloted form, and quality assessment was conducted independently by two authors. The risk of bias was assessed in studies other than case reports or case series using the critical appraisal instrument for studies reporting prevalence data. Narrative techniques were used for data analysis and, where appropriate, meta-analysis using a fixed-effects model was performed. Results: Of 509 studies screened, 105 full-text articles were assessed, with 46 papers subsequently excluded, resulting in 59 analysed in depth. There were 105 patients with RCC reported as having a cough due to the disease itself within 30 case reports and 8 case series. When present, most coughs were described as persistent and dry in nature. The cause of cough was attributed to various aetiologies including pulmonary and endobronchial metastasis and paraneoplastic syndromes. Studies reporting patients with RCC developing a cough because of systemic treatment were heterogeneous. Two studies with 238 patients on temsirolimus and 230 on interferon-α (IFN-α) were suitable for meta-analysis using a fixed-effects model. Patients on temsirolimus were more likely to develop a cough than those on IFN-α (OR 1.95 with a 95% CI of 1.05 to 3.63, overall effect Z=2.12 (p=0.03), I 2 =0%). Conclusion: Cough can occur in patients with RCC, as part of the disease pathogenesis, as an adverse effect of systemic treatment or due to unrelated causes such as pre-existing conditions (eg, asthma). Further research is required to determine the true prevalence and cause and to assess whether cough could be a presenting symptom for RCC. PROSPERO registration number: CRD42022302962.